
One minute to ignite new thinking in COPD
- Article
- Campus Sanofi
- Apr 1, 2024
In a roundtable chaired by Professor Paola Rogliani, Dr. Marc Miravitlles highlighted the need for personalized COPD therapies, improved diagnostics, and greater awareness of non-smoking risk factors to better manage exacerbations and disease progression.
The article "How do different inflammatory pathways in COPD impact disease pathobiology and progression?" features insights from a round table discussion involving leading respiratory experts. It focuses on chronic obstructive pulmonary disease (COPD), a heterogeneous and progressive condition. The experts delved into the inflammatory processes in COPD, particularly type 2 pathway and its associated endotype, emphasizing the importance of identifying patients by endotypes.
Exacerbations are key events in COPD1 that play a crucial role in disease progression. Although often managed in outpatient settings, exacerbations contribute significantly to the overall burden of COPD.2 These events are characterized by an acute worsening of respiratory symptoms, including increased dyspnea associated with cough and production of purulent sputum, increased wheezing and chest discomfort.1,3 These characteristics reflect an underlying inflammatory response2 that exacerbates the disease process.